Unexpected Activity of a Novel Kunitz-Type Inhibtior: Inhibition of Cysteine Proteases but not Serine Proteases by Smith, David et al.
Unexpected Activity of a Novel Kunitz-Type Inhibtior: Inhibition
of Cysteine Proteases but not Serine Proteases
Smith, D., Tikhonova, I. G., Jewhurst, H. L., Drysdale, O. C., Dvorak, J., Robinson, M. W., ... Dalton, J. P.
(2016). Unexpected Activity of a Novel Kunitz-Type Inhibtior: Inhibition of Cysteine Proteases but not Serine
Proteases. The Journal of biological chemistry. DOI: 10.1074/jbc.M116.724344
Published in:
The Journal of biological chemistry
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright the authors 2016. This is an open access article published under a Creative Commons Attribution License
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the
author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
Unexpected Activity of a Novel Kunitz-type Inhibitor
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Kunitz-type (KT) protease inhibitors are low molecular
weight proteins classically defined as serine protease inhibitors.
We identified a novel secreted KT inhibitor associated with the
gut and parenchymal tissues of the infective juvenile stage of
Fasciola hepatica, a helminth parasite ofmedical and veterinary
importance.Unexpectedly, recombinantKT inhibitor (rFhKT1)
exhibited no inhibitory activity toward serine proteases but was
a potent inhibitor of the major secreted cathepsin L cysteine
proteases of F. hepatica, FhCL1 and FhCL2, and of human
cathepsins L andK (Ki 0.4-27 nM). FhKT1 prevented the auto-
catalytic activation of FhCL1 and FhCL2 and formed stable
complexes with the mature enzymes. Pulldown experiments
from adult parasite culture medium showed that rFhKT1 inter-
acts specifically with native secreted FhCL1, FhCL2, and FhCL5.
Substitution of the unusual P1Leu15within the exposed reactive
loopof FhKT1 for themore commonly foundArg (FhKT1Leu15/
Arg15) hadmodest adverse effects on the cysteine protease inhi-
bition but conferred potent activity against the serine protease
trypsin (Ki  1.5 nM). Computational docking and sequence
analysis providedhypotheses for the exclusive bindingof FhKT1
to cysteine proteases, the importance of the Leu15 in anchoring
the inhibitor into the S2 active site pocket, and the inhibitor’s
selectivity toward FhCL1, FhCL2, and human cathepsins L and
K. FhKT1 represents a novel evolutionary adaptation of KTpro-
tease inhibitors by F. hepatica, with its prime purpose likely in
the regulation of the major parasite-secreted proteases and/or
cathepsin L-like proteases of its host.
Fasciola hepatica is a zoonotic parasitic helminth common
in temperate and sub-tropical regions of the world. The para-
site is responsible for causing the disease fasciolosis in hun-
dreds of millions of livestock, principally sheep and cattle. This
results in reduced feed conversion, decreased dairy production,
inferior meat quality and parasite-related mortality, thus cost-
ing the agricultural industry an estimated United States $3 bil-
lion annually (1, 2). F. hepatica is also estimated to infect up to
17 million people throughout the world, primarily in develop-
ing countries, with180 million at risk of infection (3, 4). The
mammalian host becomes infected following ingestion of grass
or other vegetation contaminated with F. hepatica cysts (meta-
cercariae). The parasites then exocyst in the host duodenum
and penetrate through the intestinal wall before migrating to
the liver and bile ducts. To facilitate this journey, the parasite
excretes and secretes an array of molecules that come into con-
tact with host cells and tissues, the most abundant being pro-
teases and protease inhibitors (5, 6). These molecules are
important for the parasite’s survival within its host and perform
roles in immunomodulation, immune evasion, feeding, parasite
development, and protein regulation (5–9).
Transcriptomic data analysis of the infective newly excysted
juvenile (NEJ)5 stage of F. hepatica identified a cDNA sequence
that encodes a protein with homology to a Kunitz-type (KT)
serine protease inhibitor (10). In their monomeric form, KT
protease inhibitors are typically lowmolecularmass proteins of
6–8 kDa. They contain six cysteine residues that form three
conserved disulfide bonds in a 1–6, 2–4, and 3–5 arrangement
that maintains structural integrity of the inhibitor and allows
presentation of a protease-binding loop at its surface (see Fig. 2)
(11–13). A highly exposed P1 active site residue at position 15,
which inserts into the S1 site of the cognate protease, is located
at the peak of the binding loop and is of prime importance in
determining the specificity of serine protease inhibition (14).
The P1 site residue is usually arginine (Arg) or lysine (Lys), both
of which have a positively charged side chain (11) and are the
preferential site of interaction for the digestive protease trypsin;
thus, KTprotease inhibitors are classically associatedwith tryp-
sin inhibition (e.g. bovine pancreatic trypsin inhibitor, BPTI)
(15–17). Other serine proteases often inhibited by KT inhibi-
tors include the digestive enzyme chymotrypsin, neutrophil
elastase, and several serine proteases involved in the blood
coagulation cascade, such as thrombin, kallikrein, and various
other tissue factors (12, 17–21). The P1 residue in the F. hepat-
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ica KT is a leucine (Leu), which has been found in certain KT
inhibitors that have a greater specificity for chymotrypsin over
trypsin (11).
Although genes encoding KT protease inhibitors have been
identified in a number of parasitic organisms (11), only a few
have been characterized functionally. However, because of
their putative protease-inhibition properties, they are proposed
to be important in parasite defense (11). For example, in intes-
tinal nematodes such as hookworms (22–24) and cestodes such
asEchinococcus granulosus (25, 26), KTprotease inhibitorsmay
protect the parasite by inhibiting potentially harmful host
digestive enzymes. However, in the guts of blood-feeding schis-
tosome parasites (27, 28) and the secretions of biting insects
(29) and ticks (30–32), KT inhibitors are suggested to obstruct
blood coagulation enzymes to prevent blood clotting. A KT
inhibitor with trypsin inhibitory activity has previously been
identified in soluble extracts of adult F. hepatica taken from the
bile ducts of ruminants (33), but its function remains obscure as
it exhibited no activity against the major coagulation enzymes
and only low activity (Ki 143 nM) against trypsin.
Here, we report the discovery of a KT protease inhibitor
(FhKT1) from the infective and tissue invasive stage of F. hepat-
ica that exhibits no inhibitory activity against serine proteases
but has potent activity against cathepsin L-like cysteine pro-
teases. Substitution of the atypical P1 Leu15 that projects from
the exposed reactive loop of the inhibitor with an Arg residue
modestly reduces its cysteine protease inhibition profile but
endows the protein with trypsin-inhibitory activity. Molecular
modeling of the interaction of FhKT1 with the major secreted
parasite cathepsin L cysteine proteases and human cathepsin
L-like cysteine proteases indicated the importance of the P1
Leu15 in docking the inhibitor into the S2 active site of these
enzymes and suggested key inhibitor-enzyme interactions that
impart FhKT1 its unique inhibitory properties.
Results
Expression of fhkt1 in Newly Excysted Juveniles in F.
hepatica—Transcriptome analysis of the newly excysted juve-
nile stage showed that fhkt1 is expressed by the early F. hepatica
stages that invade the host. Differential gene expression analy-
sis during the first 24 h post-excystment shows that fhkt1 gene
is up-regulated in NEJs 24 h post-excystment compared with
NEJs 3 h post-excystment (Fig. 1A).Western blot analysis using
anti-FhKT1 antibodies revealed an7-kDa band inmedium in
which NEJs were cultured for 24 h (Fig. 1B, lane 2), confirming
that FhKT1 is secreted by this parasite the 1st day after excyst-
ment. Mass spectrometry analysis of NEJ-secreted products
revealed that FhKT1 is released into medium by both 3- and
24-h post-excystment NEJs (Fig. 1C and supplemental file 1).
To localize FhKT1 expression within the NEJ, confocal
microscopy was carried out on 3- and 24-h post-excystment
NEJs. These were probed with polyclonal anti-FhKT1 antibod-
ies and counter-stained with TRITC-labeled phalloidin to pro-
videNEJ structural visualization ofmuscle tissue under fluores-
cence microscopy. Little fluorescence was observed in NEJs 3 h
post-excystment using anti-FhKT1 (Fig. 1D, panels ii and iii).
By contrast, in NEJs 24 h post-excystment, bright fluorescence
was observed in the parenchymal tissue and particularly con-
centrated in parenchymal cell bodies (white arrowheads) (Fig.
1D, panels v and vi). Diffuse staining was observed within the
NEJ gut (black arrowheads) (Fig. 1D, panels v and vi). This
increase in fluorescence in 24-h NEJs compared with 3-h NEJs
is consistent with the up-regulated transcript and protein
expression observed in 24-h NEJs (Fig. 1, A and C). No FITC
fluorescence was observed in negative control NEJs (3 and 24 h
post-excystment) probed with pre-immune sera (Fig. 1D, pan-
els i and iv).
F. hepatica Inhibitor FhKT1 Exhibits a Unique Specificity for
Cysteine Proteases—Surrogate expression of the fhkt1 gene in
the yeast Pichia pastoris allowed us to produce and purify a
recombinant form of the inhibitor (rFhKT1, Fig. 2). Surpris-
ingly, in our initial screens we found that the purified rFhKT1
did not exhibit any inhibition against a variety of standard ser-
ine proteases, including trypsin, chymotrypsin, elastase, throm-
bin, kallikrein, and human cathepsin G (Fig. 3A). This was not
due to the recombinant protein being functionally inactive as
we subsequently discovered that rFhKT1was a potent inhibitor
of two F. hepatica cathepsin L-like cysteine proteases, FhCL1
and FhCL2. In further screens, rFhKT1 was shown to inhibit
human cathepsin L and cathepsin K (Fig. 3A). In these initial
inhibition screens, rFhKT1 was tested at 300 nM, and the activ-
ity of FhCL1, FhCL2, and human cathepsins K and L was
reduced by 98.86% (0.205), 90.29% (0.025), 99.54% (0.08),
and 96.79% (0.09), respectively (Fig. 3A). Of further relevance
was our observations that at a 300 nM final concentration
rFhKT1 did not show any inhibition of F. hepatica cathepsin B1
(FhCB1) and B2 (FhCB2) or of human cathepsin B and cathep-
sin S (Table 1). In parallel assays, we showed that the activity of
trypsin, chymotrypsin, neutrophil elastase, and cathepsin G
was completely inhibited by 300 nM BPTI and that thrombin
and kallikrein were completely inhibited by 0.002 units of hiru-
din (data not shown). Given that the concentration of FhKT1
inhibitor required for the inhibition of the cathepsin L and K
cysteine proteases was found to be lower than the concentra-
tion of enzyme required to produce a reliable activity curve in
fluorogenic assays, these were considered to be tight-binding
inhibitors, and thus enzymatic data were fitted to theMorrison
equation (Fig. 4). ResultingKiapp valueswere fitted to Equation 2
mentioned above to determine Ki values. Kinetic inhibition
constants determined at pH 5.5 for rFhKT1 against the two
parasite proteases differed substantially; the Ki for FhCL1 was
0.4 (0.1) nM and for FhCL2 was 10 (0.3) nM. The inhibition
constant was 1.6 (0.1) nM for human cathepsin L and 5 (0.3)
nM for human cathepsin K (Table 1).
Impact of Substituting the FhKT1 P1 Leu Residue to Arg on
Protease Inhibition—Given the importance of the P1 residue at
position 15 within the exposed loop in KT protease inhibitors,
we examined the impact of substituting this residue in FhKT1
from a leucine to the more commonly found arginine. This
variant form, termed rFhKT1Leu15/Arg15, retained its ability to
inhibit F. hepatica FhCL1 and FhCL2 and human cathepsin L
and K, but as with the wild-type rFhKT1, it did not inhibit
FhCB1 and FhCB2 and human cathepsin B and S (Table 1).
However, several key observations were made, including the
following: (a) rFhKT1Leu15/Arg15 was less inhibitory than
rFhKT1 with Ki 2–3-fold higher against the parasite and mam-
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malian cysteine proteases (Table 1); (b) although the inhibition
of FhCL1 and FhCL2 by both rFhKT1 and rFhKT1Leu15/Arg15
was effective over a broad pH range of 4.5–8.0 and optimal at
neutral pH, the variant inhibitor was less effective in the lower
pH range (Fig. 3,B andC); (c) in contrast to rFhKT1, the variant
rFhKT1Leu15/Arg15 possessed potent inhibitory activity
against the serine protease trypsin, with trypsin activity
reduced by 88.92% (0.89) in assays performed at 300 nM
inhibitor (Fig. 3A). rFhKT1Leu15/Arg15 exhibited aKi of 1.5 nM
(0.7 nM) against trypsin (Table 1), which demonstrates that
the substitution of Leu to Arg is sufficient to endow this inhib-
itor with the ability to bind within the active site of this serine
protease. However, it is noteworthy that this inhibitory con-
stant is still 10 times higher than that recorded for BPTI (0.15
nM), and even at 300 nM, rFhKT1Leu15/Arg15 did not show any
inhibition toward the other serine proteases tested, including
chymotrypsin, elastase, thrombin, kallikrein, and human
cathepsin G (Fig. 3A).
rFhKT1 Prevents the Auto-catalytic Activation of Parasite
Cysteine Proteases—The parasite cysteine proteases FhCL1 and
FhCL2 are produced as inactive 37-kDa zymogens (Fig. 5, lane
1) that can be auto-catalytically activated in vitro at pH 4.5 (34).
To determine whether rFhKT1 and rFhKT1Leu15/Arg15 could
regulate the activation of the parasite proteases, these inhibi-
tors weremixed with zymogens of FhCL1 and FhCL2 at pH 4.5,
and the activation was monitored by LDS-PAGE. After 45 min
of incubation at 37 °C in citrate phosphate buffer, pH 4.5,
FhCL1 auto-activates to give rise to an25-kDa mature active
form and a released 6-kDa propeptide (Fig. 5, lane 2). Incuba-
tion of FhCL1 with rFhKT1 or rFhKT1Leu15/Arg15 prevented
the appearance of both of these bands indicating that auto-
catalytic cleavage was prevented (Fig. 5, lanes 3 and 4). Similar
results were observed for FhCL2 (data not shown). For compar-
ison, we showed that co-incubation of FhCL1 with the KT
inhibitor BPTI did not prevent auto-catalytic activation of the
zymogen (Fig. 5, lane 5).
FIGURE 1. FhKT1 is a temporally regulated and secreted protein in F. hepaticaNEJ. A, graphical representation of fhkt1 expression within NEJs 3 and 24 h
post-excystment in transcripts per kilobasemillion (TPM). Error bars indicate standard deviation of two separate experiments. B,Western blot analysis of RPMI
1640 culture medium from F. hepatica NEJs cultured for 24 h. Following the transfer of protein from LDS-polyacrylamide gel onto a nitrocellulose membrane
byWestern blotting, blots were spliced and probedwith pre-immunemouse antiserum (lane 1) and anti-FhKT1monoclonal antibodies raised inmice (lane 2).
The immunoreactive band in lane 2 corresponding to FhKT1 is indicated by a gray arrow. M, molecular mass marker. C, graphical representation of mass
spectrometry analysis of FhKT1present in RPMI 1640 culturemedium from F. hepaticaNEJs cultured for 3 and24h, shownasuniquepeptidenumber. Error bars
indicate standarddeviationof three separate experiments.D, immunolocalizationof FhKT1 inNEJs by confocal scanning lasermicroscopy. NEJswere fixed and
stained as described under “Experimental Procedures.” FhKT1 expression in NEJs from two time points were compared, 3 h post-excystment (panels i–iii) and
24 h post-excystment (panels iv–vi). Fixed NEJs were probed with either anti-FhKT1 polyclonal antibodies raised in rabbit (panels ii, iii, v, and vi) or rabbit
pre-immune antiserum (negative controls, panels i and iv), followed by the secondary antibody, fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG.
No FITC stainingwas observed in the negative controls (panels i and v). Very little FITC staining (green fluorescence) was evident in the 3-hNEJs (panels ii and iii).
FITC staining was observed in 24-h NEJs (panels v and vi), with FhKT1 being evident in the parenchyma (particularly concentrated in parenchymal cell bodies,
white arrowheads) and gut (black arrowheads). Panels iii and vi and high power images of panels ii and v, respectively. All specimenswere counter-stainedwith
phalloidin-tetramethylrhodamine isothiocyanate (TRITC) to stainmuscle tissue (red fluorescence) andprovide structure.OS,oral sucker;VS, ventral sucker. Scale
bars, 20 M.M,molecular mass markers.
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To examine the stability of inactivation of FhCL1 by rFhKT1
over time, FhCL1was first auto-catalytically activated at pH 4.5
and then incubated with rFhKT1 for 6 h at 37 °C in citrate
phosphate buffer, pH 5.5, in the presence of substrate; the reac-
tion wasmonitored by the release of the fluorophore (7-amino-
4-methylcoumarin), and samples of the reactions were ana-
FIGURE 2. Structural representation of FhKT1 and FhKT1Leu15/Arg15 and their recombinant expression. A, sequence alignment of BPTI, FhKT1, and
FhKT1Leu15/Arg15. Theasteriskdenotes theP1 site at position15. Lines indicate the conserveddisulfidebonds that occur betweenCys1 andCys6, Cys2 andCys4,
andCys3 andCys5,with cysteine residues highlighted inblack bars. B, recombinant formsof FhKT1 and FhKT1Leu15/Arg15were expressed as secretory proteins
in the methylotrophic yeast P. pastoriswith a yield of5–10mg of soluble protein from each 1 liter of culture. rFhKT1 (lane 1) and rFhKT1Leu15/Arg15 (lane 2)
were isolated by NTA-affinity chromatography and analyzed by NuPAGE Novex 4–12% BisTris protein gel, stained with Biosafe Coomassie (Bio-Rad). C,
homologymodel of FhKT1 built based on BPTI (PDB code 3OTJ) displaying the three disulfide bonds (yellow), the-helix (red), and anti-parallel-sheets (blue)
characteristic of KT protease inhibitors. The P1 Leu15 located at the peak of the reactive loop is also shown in gray.
FIGURE 3. Inhibition profile of FhKT1 and FhKT1Leu15/Arg15 against cysteine and serine proteases. A, inhibitory activity of rFhKT1 (black bars) and
rFhKT1Leu15/Arg15 (gray bars) at 300 nMwas screened using a range of cysteine proteases, including F. hepatica cathepsin L1 (FhCL1), F. hepatica cathepsin L2
(FhCL2), F. hepatica cathepsin B1 (FhCB1), F. hepatica cathepsin B2 (FhCB2), human cathepsin K (HsCK), human cathepsin L (HsCL), human cathepsin B (HsCB),
human cathepsin S (HsCS), and serine proteases, including trypsin, chymotrypsin, neutrophil elastase (NE), cathepsin G, thrombin, and kallikrein. Inhibition is
presented relative to theactivity of eachenzyme in theabsenceof inhibitors.B, activity of FhCL1 in thepresenceof 300nM rFhKT1 (blackbars) and rFhKT1Leu15/
Arg15 (gray bars) at different pH values (see “Experimental Procedures” for details of buffer systems) relative to FhCL1 activity in the absence of inhibitors. C,
activity of FhCL2 in thepresenceof 300nM rFhKT1 (black bars) and rFhKT1Leu15/Arg15 (gray bars) at different pHvalues, relative to FhCL2 activity in the absence
of inhibitors. Error bars indicate standard deviation of three separate experiments.
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lyzed byLDS-PAGE (Fig. 6). rFhKT1 completely inactivated the
FhCL1, and this inactivation was stable for the entire 6 h (Fig.
6A). Furthermore, the rFhKT1 remained intact over this time
and was observed as a band at6 kDa. However, a minor band
at5 kDa was observed at the 2- and 6-h time points (Fig. 6B).
This band was not immunoreactive with anti-His tagmonoclo-
nal antibodies (Fig. 6D), but it was reactive with anti-rFhKT1
polyclonal antibodies (Fig. 6C), showing that this protein
results from proteolytic clipping at the C terminus of rFhKT1
by FhCL1. A similar cleavage pattern was observed with
rFhKT1Leu15/Arg15 and alsowhen FhCL2was used in the reac-
tions (data not shown).
Inhibition assays that were extended for up to 7 days showed
that FhCL1 activity remained inhibited by rFhKT1 over this
prolonged period. However, the activity of mature FhCL1 (in
the absence of inhibitor) depleted by 99% over the course of
the experiment, with activity reduced from 21,271.27 (
961.52) RfU/min at 0 days to 65.73 ( 14.49) RfU/min at day 7
(data not shown).
Inhibitory Activity of rFhKT1 Is Dependent on Internal Disul-
fide Bridges—Reduction and alkylation of both rFhKT1 and
rFhKT1Leu15/Arg15 were performed to break internal disulfide
bridges and to disrupt the tertiary structure of the protein. This
procedure depleted the inhibitory activity of both inhibitors
against FhCL1 (Fig. 7A). Similarly, this treatment ablated the
inhibitory activity of rFhKT1Leu15/Arg15 against trypsin (Fig.
7B). Interestingly, we discovered that both rFhKT1 and
rFhKT1Leu15/Arg15 could partially re-nature to their func-
tional form during a 10-day incubation period at 4 °C; over this
time, the inhibitors regained between 60 and 80%of their inhib-
itory activity (Fig. 7A). Likewise, rFhKT1Leu15/Arg15 regained
inhibitory activity against trypsin (Fig. 7B).
rFhKT1 Interacts with Several Native F. hepatica Cysteine
Proteases—Adult F. hepatica parasites secrete several cysteine
proteases, both in vivo and in vitro. To demonstrate that FhKT1
can bind and inhibit native parasite proteases, the inhibitors
were mixed with culture medium in which adult F. hepatica
TABLE 1
rFhKT1and rFhKT1Leu15/Arg15 inhibition specificity against apanelofbiologically relevant serineandcysteineproteasesand relative inhibition
constants
Enzyme (concentration)
rFhKT1 rFhKT1Leu15/Arg15
Inhibition Ki Inhibition Ki
Cysteine proteases
F. hepatica cathepsin L1 (2.7 nM)  0.4 nM ( 0.1 nM)  0.7 nM ( 0.04 nM)
F. hepatica cathepsin L2 (5 nM)  10 nM ( 0.3 nM)  27 nM ( 1.5 nM)
F. hepatica cathepsin B1 (180 nM)  Not inhibited  Not inhibited
F. hepatica cathepsin B2 (180 nM)  Not inhibited  Not inhibited
Human cathepsin L (0.2 nM)  1.6 nM ( 0.1 nM)  3 nM ( 0.1 nM)
Human cathepsin K (2 nM)  5 nM ( 0.3 nM)  10 nM ( 0.2 nM)
Human cathepsin S (2 nM)  Not inhibited  Not inhibited
Human cathepsin B (3.6 nM)  Not inhibited  Not inhibited
Serine proteases
Trypsin (42 nM)  Not inhibited  1.5 nM ( 0.7 nM)
Chymotrypsin (40 nM)  Not inhibited  Not inhibited
Neutrophil elastase (50 nM)  Not inhibited  Not inhibited
Cathepsin G (100 nM)  Not inhibited  Not inhibited
Thrombin (43 pM)  Not inhibited  Not inhibited
Kallikrein (150 nM)  Not inhibited  Not inhibited
FIGURE 4. Plot of F. hepatica cathepsin L1 proteolytic activity with the
substrate Z-Leu-Arg-NHMec, as a function of inhibitor concentration for
rFhKT1 (solid circles) and rFhKT1Leu15/Arg15 (clear circles).The curves rep-
resent the best fit to theMorrison equation (solid line rFhKT1; dashed line
rFhKT1Leu15/Arg15). Error bars indicate standard deviation of three separate
experiments. FIGURE 5. Inhibition of the auto-catalytic activation of FhCL1 by rFhKT1
and rFhKT1Leu15/Arg15.M,molecularmassmarker; lane 1, FhCL1 zymogen;
lane 2,mature FhCL1 following auto-catalytic activation at pH 4.5 for 1 h; lane
3, FhCL1 and rFhKT1 following incubation at pH 4.5 for 1 h; lane 4, FhCL1 and
rFhKT1Leu15/Arg15 following incubation at pH 4.5 for 1 h; lane 5, FhCL1 and
bovine pancreatic trypsin inhibitor following incubation at pH 4.5 for 1 h.
Double white arrowhead indicates FhCL1 zymogen; double gray arrowhead
indicates mature FhCL1, and double black arrowhead indicates FhCL1 pro-
peptide removed following auto-catalytic activation. Single white arrowhead
indicates position of FhKT1; single black arrowhead indicates FhKT1Leu15/
Arg15, and single gray arrowhead shows position of BPTI. Proteins were sepa-
rated on a NuPAGENovex 4–12%BisTris protein gel and stainedwith Biosafe
Coomassie (Bio-Rad).M,molecular mass markers.
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parasites had beenmaintained (F. hepatica excretory-secretory
proteins), and activity was monitored using Z-Phe-Arg-
NHMec as substrate; both inhibitors blocked 80% of total
secreted cathepsin L-like activity (Fig. 8A).
To identify the native cysteine proteases to which rFhKT1
bound, this inhibitor was added to media in which adult para-
sites were cultured for 5 h. Following the parasite culture, the
media were removed, and rFhKT1 was pulled down with Ni-
NTA beads; fluorogenic assays demonstrated that removal of
the inhibitors from each medium, respectively, also resulted in
the depletion of95% of the cysteine protease activity secreted
by the adult parasites (Fig. 8B). LDS-PAGE analysis of the pro-
teins bound to the Ni-NTA beads revealed a 6-kDa band rep-
resenting the rFhKT1 and another band of25 kDa, which is in
keeping with the size of mature cathepsin L cysteine proteases
(Fig. 8C). The 6- and25-kDa proteinswere not detectedwhen
Ni-NTA beads were added to the culture media containing no
recombinant inhibitor. LC-MS/MS analysis verified that the
25-kDa band pulled down by rFhKT1 consisted of a mix of
F. hepatica cysteine proteases in their mature forms, including
FhCL1, FhCL2, and another cathepsin L protease known as
FhCL5 (supplemental file 2) (6, 35).
FhKT1 Binds to the Cysteine Protease Active Site in a Unique
Manner—Tounderstand themolecular basis of FhKT1 binding
to cathepsins, a homology model of FhKT1 was built using the
crystal structure of BPTI as a template. Although protein
sequence identity between BPTI and FhKT1 is only 23%, both
possess the six conserved cysteine residues that form three
disulfide bonds (11), suggesting similar folding (root mean
square deviation 1.3 Å). The homology model of FhKT1 was
docked to the crystal structure of FhCL1 previously reported by
us (36). The rigid body protein-protein docking protocol was
employed, and the selected docking solution was optimized
using molecular dynamic simulations. A docking solution in
which the P1 Leu15-containing side of FhKT1 faces the active
site of FhCL1, similar to the BPTI binding orientation in trypsin
in the crystal structure, was used for optimization. The result-
FIGURE 6. rFhKT1 inhibits mature FhCL1 and forms a stable complex. A,
progress curve of fully activated FhCL1 inhibited by rFhKT1 over 360 min.
Activity is represented by relative fluorescent units. Activity of uninhibited
FhCL1 is represented by the solid line, and rFhKT1-inhibited FhCL1 is repre-
sented by the dashed line. Error bars indicate standard deviation of three sep-
arate experiments.B, FhCL1 zymogen (lane 1) was auto-catalytically activated
at pH4.5 for 1 h to themature active enzyme (lane 2). Themature enzymewas
then incubated in the absence (lanes 3–5) or presence (lanes 6–8) of rFhKT1
for 1 h (lanes 3 and 6), 2 h (lanes 4 and 7), and 6 h (lanes 5 and 8), and then the
reactionmixes were analyzed by LDS-PAGE. The protein gel was stainedwith
Biosafe Coomassie (Bio-Rad). Replicate gels were used for Western blot anal-
ysis by probing with polyclonal anti-rFhKT1 (C) and polyclonal antibody to
His6-tagged proteins polyclonal antibodies (D). The arrowhead indicates the
position of a cleaved product of 5-kDa band that reacts with polyclonal
anti-rFhKT1 but not anti-His6-tagged antibodies indicating that it represents
a cleavage product of rFhKT1.M,molecular mass markers.
FIGURE 7. Inhibitory activity of rFhKT1 and rFhKT1Leu15/Arg15 is depen-
dent on disulfide bridges. A, inhibition of FhCL1 activity by rFhKT1 and
rFhKT1Leu15/Arg15 before (black bars) and after reduction (R) and alkylation
(A) (light gray bars) and with reduced and alkylated inhibitor following incu-
bation for 10 days at 4 °C (dark gray bars). B, inhibition of trypsin activity by
rFhKT1Leu15/Arg15 before (pre-reduction and alkylation (R/A), black bars) and
after reduction and alkylation (R/A, light gray bars), and with reduced and
alkylated inhibitor following incubation for 10 days at 4 °C (post-R/A, dark
gray bars). Error bars indicate standard deviation.
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ant protein-protein complex indicates that FhKT1 binds suffi-
ciently tight within the active site groove of FhCL1 to block
access of small substrates (e.g. Z-Phe-Arg-NHMec) to the reac-
tive cysteine (Cys132) in the S1 active site pocket (Fig. 9, A
and B).
In this model of interactions, the residue Leu15 of the
exposed loop of FhKT1 forms strong hydrophobic interactions
with residues Leu176, Met177, and Val267 of the S2 pocket of
FhCL1 (Fig. 9, A and B). This places Gly16 and Gly17 across the
S1 pocket, but neither penetrates this subsite. The Ile18 is not
predicted to make any interactions with the FhCL1, but Arg19
forms an H-bond with the Asn128 of the S2 pocket. Relevantly,
the sequence alignment of the cysteine proteases (Tables 2 and
3 and Fig. 10) used in this study shows that residues of the S2
and S1-S2 pockets are highly similar in physicochemical
properties in FhCL1, FhCL2, human cathepsins L and K, which
are all inhibited by FhKT1. By contrast, these residues are
diverse in F. hepatica cathepsins FhCB1 and FhCB2, and in
human cathepsins B and S, which are not inhibited by FhKT1
(Tables 2 and 3 and Fig. 10). This observation suggests that the
S2 and S1-S2 pockets play a crucial role in selective binding of
FhKT1 to FhCL1, FhCL2, and human cathepsins L and K.
The binding orientation we obtained for the P1 Leu15 helps
explain the interactions of Arg at this position in the variant
rFhKT1Leu15/Arg15. The hydrophobic tail of Arg15 can form
hydrophobic interactions with the S2 pocket, whereas the gua-
nidine group could formH-bonds with Glu178 of FhCL1 (Fig. 9,
C andD). Intriguingly, the other cathepsins that we have shown
to bind FhKT1Leu15/Arg15, i.e. FhCL2 and human cathepsins L
and K, also have a residue capable of forming H-bonds at this
position (Table 2 and Fig. 10).
Unlike BPTI, FhKT1 does not bind to trypsin and other ser-
ine proteases tested in this study. In the available crystal struc-
tures of the BPTI-trypsin complex, the P1 Lys15 of BPTI forms
H-bonds with Asp194 and Ser195 of the trypsin S1 (37). How-
ever, the hydrophobic P1 Leu15 of FhKT1 is unlikely to bind
to the hydrophilic S1 pocket of serine proteases preventing
the formation of the protein-protein complex. Binding of
rFhKT1Leu15/Arg15 to trypsin, however, suggests that the P1
Arg15 can form these crucial H-bonds in the S1 pocket.
Kunitz inhibitors with P1 Leu often exhibit an increased
specificity for chymotrypsin over trypsin (11). In this study,
however, we found that FhKT with a P1 Leu15 does not inhibit
chymotrypsin. Our modeling of these two molecules suggests
that this could be due to different structuring of surface poly-
peptide loops of FhKT1 and chymotrypsin that are unable to
establish a complementary interface to form a complex and
allow the P1 Leu15 to enter the active site.
Discussion
We have shown that the infective stage of the helminth par-
asite F. hepatica expresses a temporally regulated and secreted
Kunitz-type (KT) protease inhibitor (FhKT1) with novel inhi-
bition properties. Unlike any previously described KT protease
inhibitors, FhKT1 exhibits exclusive and stable inhibition of
cysteine proteases, specifically cathepsin L- and K-like cysteine
proteases. Recombinant FhKT1 inhibits these cysteine pro-
teases across a wide pH range, from pH 4.5 to 8.5, with optimal
inhibition at neutral pH. Our studies suggest that the six con-
served cysteine residues that maintain the structural integrity
of the central domain of KT-type inhibitors perform a similar
FIGURE 8. rFhKT1 binds and inhibits native F. hepatica-secreted cysteine proteases. A, cysteine protease activity (presented as RfU) in adult F. hepatica
RPMI 1640 culture media measured with the fluorogenic peptide substrate, Z-Phe-Arg-NHMec, in the absence (circles) or presence of rFhKT1 (squares) or
rFhKT1Leu15/Arg15 (triangles). B, cysteine protease activity in the adult F. hepatica RPMI 1640 culture media following pulldown using Ni-NTA beads alone
(circles), rFhKT1 and Ni-NTA beads (squares), or rFhKT1Leu15/Arg15 and Ni-NTA beads (triangles). C, LDS-PAGE analysis of pulldown from adult F. hepatica RPMI
1640 culturemedia with Ni-NTA beads alone (lane 1) andwith rFhKT1 andNi-NTA beads (lane 2), stainedwith Biosafe Coomassie (Bio-Rad). LC-MS/MS analysis
of the 26-kDa band observed in lane 2 revealed that it consisted of FhCL1, FhCL2, and FhCL5 in their fully active mature forms.M,molecular mass marker.
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FIGURE 9.Molecularmodel of FhKT1-F. hepatica cathepsin L1 interactions. The homologymodel of FhKT1 (A and B) and FhKT1Leu15/Arg15 (C andD) built
based on BPTI (PDB code 3OTJ) and the crystal structure of F. hepatica cathepsin L (PDB code 2O6X) are shown in pink and gray schematics, respectively. The
interacting residues of FhKT1 and FhCL1, the residues of the FhCL1 S1 pocket (Cys132, His269, andAsn289), and the residues of the S2pocket (Gln126, Gly127, and
Asn128) and Glu178 are visualized in stick-like representation. The residues of the S2 pocket, the residues of S2 pocket, and other interacting residues of FhCL1
are shown in purple, green, and gray, respectively. Hydrogenbonds andhydrophobic interactions are in black and green, respectively. Residue labels are in blue
for FhKT1 and black for FhCL1. A and B, Leu15 of FhKT1 is predicted to sit in the hydrophobic S2 pocket of FhCL1, forming contacts with Leu176, Met177, and
Val267. In addition, it is indicated that FhKT1 forms H-bonds with Asn128 of the S2 pocket. It is also predicted that Gly16 and Gly17 block substrate access to the
S1 active site pocket by being positioned across it, without actually penetrating the pocket. C and D, Arg15 of FhKT1Leu15/Arg15 is predicted to sit in the
hydrophobic S2 pocket of FhCL1, forming contacts with Leu176, Met177, and Val267. The guanidine group of Arg15 is predicted to interact with Glu178 via
H-bonds. In addition, as for FhKT1 it is also indicated that Gly16 andGly17 sit across the S1 active site pocketwithout penetrating the pocket itself, thus blocking
substrate access. FhKT1Leu15/Arg15 is also predicted to formH-bonds with Asn128 of the S2 pocket. Panels at right are enlarged versions of the left, with focus
toward the FhCL1 active site.
TABLE 2
Comparison of residues forming the S2 active site of cysteine proteases from F. hepatica and H. sapiens
S2 residuesa
176 177 242 267 270 316
F. hepatica CL1 Leu Met Ala Val Ala Leu
F. hepatica CL2 Tyr Met Ala Leu Ala Leu
Human cathepsin K Tyr Met Ala Leu Ala Leu
Human cathepsin L Leu Met Ala Met Gly Ala
F. hepatica CB1 Gln Cys Gly Gly Ala N/A
F. hepatica CB2 Lys Cys Thr Gly Ala N/A
Human cathepsin S Phe Met Gly Val Gly Phe
Human cathepsin B Pro Cys Ala Gly Ala Val
a Residue numbering is based on FhCL1 (shown in pink in Fig. 10).
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function in FhKT1 as reduction and alkylation of the disulfide
cross-links abrogate inhibitory activity.
Previously, we resolved the three-dimensional structure of
FhCL1 and showed that the active site is typical of the cathepsin
L cysteine proteases, consisting of a deep open groove created
between the right and left domains of the enzyme (36). Here, we
built a homology model of FhKT1 on the basis of the known
BPTI structure and docked it into the FhCL1 active site to pro-
vide insights into the interactions responsible for the binding of
FhKT1 to cathepsin L-like proteases. The P1 Leu15 in FhKT1,
which projects from the peak of the inhibitor reactive loop, is
predicted to form crucial hydrophobic interactions with resi-
dues in the FhCL1 S2 active site pocket (Leu176, Met177, and
Val267), whereas residue Arg19 of FhKT1 is predicted to form
H-bond interactions with Asn128 within the S2 pocket, respec-
tively. Because FhKT1 spans these S and S subsites, it places
the Gly16 and Gly17 residues in a position whereby they block
access of even small molecules, such as Z-Phe-Arg-NHMec, to
the reactive Cys132 residue in the S1 pocket that is essential for
forming a thiol intermediate with the substrate before the scis-
sile bond is cleaved.
It is intriguing that FhKT1 also exhibits specificity within the
cathepsin-like cysteine proteases themselves by not inhibiting
parasite or human cathepsin B and human cathepsin S. This
specificity of inhibition was explained by our computational
modeling and sequence comparison that revealed a distinct dif-
ference in the composition of the S2 and S1-S2 active site
pockets within this group of proteases; these changes reduce
TABLE 3
Comparison of residues surrounding the S1 active site region of cysteine proteases from F. hepatica andH. sapiens (based on sequence alignment)
Residue no.a
125 126 127 128 129 130 131 132b 133 134 135 136
F. hepatica CL1 Asp Gln Gly Asn Cys Gly Ser Cys Trp Ala Phe Ser
F. hepatica CL2 Asp Gln Gly Gln Cys Gly Ser Cys Trp Ala Phe Ser
Human cathepsin K Asn Gln Gly Gln Cys Gly Ser Cys Trp Ala Phe Ser
Human cathepsin L Asn Gln Gly Gln Cys Gly Ser Cys Trp Ala Phe Ser
F. hepatica CB1 Ser Ala Ile Asp Leu Val Ser Cys Cys Ser Tyr Cys
F. hepatica CB2 Ala Ala Ala Asp Pro Leu Ser Cys Cys Thr Tyr Cys
Human cathepsin S Tyr Gln Gly Ser Cys Gly Ala Cys Trp Ala Phe Ser
Human cathepsin B Ser Ala Glu Asp Leu Leu Thr Cys Cys Gly Ser Met
a Residue numbering is based on FhCL1.
b Active site cysteine residues are shown in boldface.
FIGURE10.SequencealignmentofF. hepaticaandHomosapienscysteineproteases.F. hepatica cysteineprotease sequences includeFhCL1 (cathepsinL1,
AAB41670), FhCL2 (cathepsin L2, AAC47721), FhCB1 (cathepsin B1, ABF85678), and FhCB2 (cathepsin B2, ABF85679). H. sapiens cysteine protease sequences
include HsCK (cathepsin K, NP_000387), HsCL (cathepsin L, NP_001903), HsCS (cathepsin S, NP_004070), and HsCB (cathepsin B, NP_001899). Residues
surrounding the S1 active site region are shown in green, and residues forming the S2 active site are shown in pink. Residues that form interactionswith FhKT1
and FhKT1Leu15/Arg15 are shown in bold.
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their hydrophobicity and alter charge arrangements such that
they cannot interact with the P1 Leu15 (see Tables 2 and 3 and
Fig. 10). It is noteworthy that the occluding loop that is com-
mon in cathepsin B proteases and is responsible for conferring
these enzymes with carboxypeptidase activity (38) does not
prevent access of FhKT1 to the active site.
Although the P1 Leu15 of FhKT1 was predicted to be impor-
tant for interactions with the hydrophobic S2 pocket of the
cathepsin L-like proteases, this residue could be replaced by
Arg (FhKT1Leu15/Arg15). The P1 Arg15 did exert some adverse
effects, especially at low pH, on the inhibitor’s activity, but it did
not alter its specificity against cysteine proteases. Molecular
docking with FhCL1 indicated that the hydrophobic tail of
Arg15 could still form hydrophobic interactions with the S2
pocket, similar to those predicted for Leu15. In addition, the
guanidine group of Arg15 is predicted to form H-bonds with
Glu178. These interactions could not take place in the cathepsin
B and S proteases, and therefore, the variant showed no activity
against these enzymes. Other amino acid replacements at posi-
tion 15, however, could likely have a more dramatic effect on
the FhKT1’s inhibitory properties.
There are no previous reports of aKT-type protease inhibitor
that exclusively inhibits cysteine proteases like FhKT1,
although there are several that describe members with low
cross-activity against other proteases. For example, a KT inhib-
itor from the hard tick Boophilus microplus (BmTIsint) blocks
serine proteases (trypsin and plasma kallikrein, Ki  3.3 and
16.5 nM, respectively), as well as the cysteine protease human
cathepsin L (Ki 108 nM) (39), and the KT inhibitor (ShPI-1A)
from the sea anemone Stichodactyla helianthus exhibits broad
inhibitory specificity toward serine (trypsin Ki  0.1 nM, chy-
motrypsin Ki  2.3 nM, human plasmin Ki  2.7 nM, and por-
cine kallikrein Ki  85 nM), cysteine (Ki for papain not deter-
mined), and aspartic proteases (porcine pepsinKi 33 nM) (40,
41). Like rFhKT1Leu15/Arg15, these KT inhibitors possess at P1
Arg15 that accounts for their serine protease activity; however,
apart fromBmTIsint having aGlu39 residue at a similar position
to FhKT1, it is not possible to fully explain their cysteine pro-
tease inhibitory activity from primary sequence comparisons
alone (39). Interestingly, a KT inhibitor reported from the
blood feeding horn fly Hematobia irritans irritans has a P1
Arg15 and residues Glu10 and Arg44 similar to FhKT1 as well as
an uncommon residue at position 39 (His39) (42), which implies
that it could inhibit both serine and cysteine proteases. Clarifi-
cation of the residues involved in restricted and broad protease
inhibition will emerge as this and other KT inhibitors are more
fully characterized andwill inform the development ofmethods
for functional predictions. For now, however, we suggest that
KT inhibitors should be classified into subgroups based on their
inhibition profile, including KT serine-specific protease inhib-
itors, KT cysteine-specific protease inhibitors, KT serine/cys-
teine protease inhibitors, and even KT serine/cysteine/aspartic
protease inhibitors. Our study also points toward the opportu-
nity of designing specific and broad inhibitors against proteases
of various mechanistic classes by making defined alterations to
the basic 68-amino acid scaffold of the KT inhibitor.
To facilitate penetration of the host intestine and migration
through the liver, the infective juvenile parasite secretes an
array of temporally regulated cathepsin L proteases (36). We
have shown that the expression of FhKT1 is also highly up-reg-
ulated in the first 24 h after excystment. Protein expression was
shown by immunolocalization studies to be associated most
particularly with cells bodies within the parenchymal tissue.
The parenchymal tissues fill the spaces between the internal
organs of the parasite and are suggested to function as a flexible
cytoskeleton and an important transport system (43, 44). The
cell bodies, which are separated from each other within the
parenchymal tissue, are highlymetabolically active and contain
numerous mitochondria and Golgi complexes (44, 45). They
act as a store for carbohydrate reserves, such a glycogen, and are
important in parasite metabolism and growth as they
become depleted as the parasite develops in the first 24 h
(46). The cell bodies have contacts with the gastrodermal
cells lining the parasite gut where we detected more diffuse
labeling of the FhKT1. The up-regulation of the FhKT1 in
the cell bodies and gut correlates with the parasite’s penetra-
tion of the duodenum wall after excystment, which is fa-
cilitated by the secretion of gut cysteine proteases suggesting
that the inhibitor plays a role in controlling proteolytic activ-
ity at this crucial phase of infection.
We also showed by pulldown experiments that FhKT1 binds
and inactivates native FhCL1, FhCL2, and FhCL5 secreted by
the adult parasite and thus has broad specificity for the para-
site’s cathepsin Ls. Importantly, FhKT1 prevents the auto-cat-
alytic activation of the inactive cathepsin zymogen to the
mature active enzyme. In a similar manner to the function of
BPTI, which regulates trypsin activation and activity to prevent
excessive tissue damage in the pancreas (47), FhKT1 may con-
trol the activation of the parasite-secreted cathepsin Ls, pre-
venting aberrant activation within the parasite itself (9, 48).
Limiting cysteine protease activity would be important to the
parasite’s survival in the host, because although the enzymes
are necessary for degrading host blood and tissues, they also
make significant contributions to the clinical manifestations of
the disease, including tissue damage, hemorrhaging, and induc-
tion of inflammatory immune responses. By complexing and
inactivating excess secreted proteases, FhKT1 could also
restrict this pathology and prevent transport of damaging
proteases via the circulation that could cause tissue inflam-
mation at sites distant from the parasite. In a previous study,
Bozas et al. (33) isolated a fraction from adult F. hepatica
containing a KT inhibitor with activity against trypsin. Fur-
thermore, an F. hepatica KT inhibitor was detected among a
preparation that was isolated by affinity purification of adult
F. hepatica excretory-secretory products using anti-cysteine
protease monoclonal antibodies (MM3) (49). These studies
show that the mature parasite also expresses an FhKT and sug-
gest that the parasite producesmore than one KT inhibitor that
is possibly temporally regulated alongside the secreted cathep-
sin Ls. It is noteworthy that the parasite does not secrete any
serine proteases during its development in themammalian host
and, therefore, would not require a specific serine-protease
inhibitor.
Cysteine protease inhibitors (e.g. cystatins) have also been
implicated in the modulation of host immune responses (50,
51). We have shown that FhKT1 inhibits human cathepsins L
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and K, both of which are important proteases of the host
immune system. Human cathepsin L functions in the proteo-
lytic processing of antigens in the lysosome for presentation on
the surface of antigen-presenting cells (52–54). If taken up by
phagocytic cells, FhKT1 inhibition of human cathepsin L could
impair this processing and thus dampen adaptive cellular and
antibody responses to the parasite. Indeed, previous work in
our laboratory has shown that a similarly sized molecule (6
kDa) termedhelminth defensemolecule secreted byF. hepatica
is readily taken up by macrophages and impairs antigen pro-
cessing and presentation (55). Human cathepsin K also plays
a critical immune regulatory function as it is involved in
Toll-like receptor 9 signaling in dendritic cells (56), and
therefore its inhibition would significantly downplay den-
dritic cell activation. Interestingly, Falco´n et al. (57) recently
reported that a fraction isolated from adult F. hepatica that
prevented dendritic cell activation in mice contained a KT
protease inhibitor, leading the authors to propose that the
inhibitor may have an important role in the immune evasion
mechanisms of the parasite. Given the potential role of
FhKT1 in parasite infection, through the regulation of the
major parasite cysteine proteases and cysteine proteases
implicated in the host immune system, FhKT1 represents a
novel vaccine and drug target.
In summary, the juvenile infective stage of the helminth
F. hepatica secretes a KT protease inhibitor that atypically
lacks the ability to inhibit serine proteases while simulta-
neously possessing a unique capacity to inhibit cathepsin
L-like cysteine proteases. The particular arrangement of
functional amino acids predicted to confer this molecule
with its unique properties has provided valuable new infor-
mation and understanding of protease inhibition by KT pro-
tease inhibitors. Furthermore, it has opened up the possibil-
ity of designing new inhibitors that could target proteases of
various mechanistic classes that are important in infectious
and non-infectious diseases.
Experimental Procedures
fhkt1 Gene and Protein Expression in F. hepatica Newly
Excysted Juveniles—RNA sequencing and gene expression
analysis were carried out in duplicate for 3 and 24 h post-
excystment of NEJs as described by Cwiklinski et al. (6). The
fhkt1 gene was identified by putative annotation of the
F. hepatica gene models using in silico tools (Uniprot, Gene
Ontology (GO), and InterProScan) (6) and BLAST analysis
against the F. hepatica genome using a previously identified
adult F. hepatica Kunitz sequence (Fh_Contig2704, Young
et al. (10)). Differential fhkt1 gene expression at the 3- and
24-h NEJ life stages was investigated using transcriptome
data (European Nucleotide Archive accession number
PRJEB6687; Cwiklinski et al. (6)) mapped to the gene models
identified within the genome (represented as transcripts per
kilobase million).
NEJs (North American isolate; Baldwin Aquatics Inc.) were
cultured in RPMI 1640 medium for 24 h to obtain their secre-
tory products as described previously (5). These were concen-
trated by ultrafiltration to 1 mg/ml and stored at 80 °C.
Approximately 5g of proteinwas subjected to LDS-PAGEand
Western blotting (5) and probed with anti-FhKT1 (1:1000 dilu-
tion) raised in mice against the peptide sequence Cys-Glu-Gly-
Asn-Asp-Asn-Arg-Phe-Asp-Ser-Lys-Ser-Ser-Cys. As a nega-
tive control, another sample was probed with pre-immune
mouse antiserum at the same dilution.
NEJ-secreted products were characterized using the pro-
teomics platform of the Quebec Genomics Center, Quebec
City,Quebec, Canada. Samples of RPMI 1640medium inwhich
NEJs (NorthAmerican isolate; BaldwinAquatics Inc.) were cul-
tured for 3 and 24 h were analyzed by LC/MS-MS, performed
on a TripleTOF 5600 mass spectrometer fitted with a nanos-
pray III ion source (ABSciex Concord, Ontario, Canada), and
coupled to an Agilent 1200 HPLC. FhKT1 was identified in
MS/MS samples (three separate samples for both time points)
analyzed using Mascot version 2.4.0 (Matrix Science) set to
search a database composed of gene models identified within
the F. hepatica genome (version 1.0, 101,780 entries; Cwiklinski
et al. (6)) and validated using Scaffold (version 4.3.2) as per
Cwiklinski et al. (7).
Immunolocalization of FhKT1 in Newly Excysted Juveniles by
Confocal Microscopy—F. hepatica metacercariae (Italian iso-
late; Ridgeway Research, UK) were excysted as described (5),
and NEJs were cultured in RPMI 1640 medium (ThermoFisher
Scientific) for 3 and 24 h, respectively. The parasites were fixed
with 4% paraformaldehyde in 0.1 M PBS (Sigma) overnight at
4 °C and then washed three times with antibody diluent (AbD:
0.1 M PBS containing 0.1% (v/v) Triton X-100, 0.1% (w/v)
bovine serum albumin, and 0.1% (w/v) sodium azide). NEJs
were then incubated in 0.1 M PBS containing anti-FhKT1 anti-
serum (prepared in rabbit against the recombinant FhKT1) at a
1:500 dilution, overnight at 4 °C, followed by three washes in
AbD. As a negative control, separate samples of 3- and 24-h
NEJs were incubated in 0.1 M PBS containing rabbit pre-im-
mune antiserum at a 1:500 dilution. Following washing, all NEJ
samples were incubated in a 1:200 dilution of the secondary
antibody, fluorescein isothiocyanate (FITC)-labeled goat anti-
rabbit IgG (Sigma), overnight at 4 °C, followed by three washes
in AbD. To counter-stain muscle tissues, NEJs were incubated
in AbD containing 200 g/ml phalloidin-TRITC overnight at
4 °C. Following three final washes in AbD, NEJs were whole-
mounted in a 9:1 glycerol solution containing 0.1 M propyl gal-
late and viewed using confocal scanning laser microscopy
(Leica TCS SP5) under the HCX PLAPOCS	100 oil objective
lens. Leica type F immersion oil was used in viewing, and all
images were taken at room temperature.
Expression of Recombinant FhKT1 and FhKT1Leu15/Arg15 in
the Methylotrophic Yeast P. pastoris—The wild-type Fhepatica
KT protease inhibitor gene identified by transcriptomic analy-
sis (Fh_Contig2704, Young et al. (10); fhkt1, Cwiklinski et al.
(6)) was codon-optimized for expression in P. pastoris and syn-
thesized in the puc57 vector (GenScript). A variant of this gene
(fhkt1leu15/arg15), whereby the P1 leucine residue at position
15 was substituted to an arginine residue (see Fig. 2) was
similarly synthesized and codon-optimized for expression in
P. pastoris. Both synthesized genes did not include the hypo-
thetical N-terminal signal peptide (based on SignalP data). A
C-terminal His tag was incorporated into each gene, as well
as an N-terminal KpnI restriction site and a C-terminal MlyI
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restriction site for cloning into the yeast expression vector,
Both fhkt1 and fhkt1leu15/arg15 were transformed into One
Shot TOP10 chemically Competent Escherichia coli cells
(ThermoFisher Scientific) for propagation and ligated into
the pPink-HC vector before transformation into Pichia-
PinkTM Strain 1 cells (ThermoFisher Scientific) by electro-
poration. (1500 V for 5 ms), following the manufacturer’s
protocol. Transformed cells were streaked onto Pichia ade-
nine dropout plates and selected for protein expression, as
previously described (58).
fhkt1 and fhkt1leu15/arg15-transformed yeast cells were
grown in 1 liter of buffered glycerol-complex medium at
28 °C to an A600 of 20 and then centrifuged at 3000 	 g for 5
min at room temperature. Pellets were resuspended in 200
ml of buffered methanol-complex medium, and protein
expression was induced at 16 °C for a further 3 days by daily
addition of 2% methanol. Cells were then pelleted by centri-
fuging at 3000 	 g, and the supernatant was collected. The
supernatant was diluted 1:4 with column buffer (sodium
phosphate buffer, pH 8, 10 mM imidazole) and passed over a
column containing a 500-l bed volume of Ni-NTA beads
(Qiagen) at a rate of 0.5 ml/min. The column was washed
with 10 ml of wash buffer (50 mM sodium phosphate buffer,
pH 8, 20mM imidazole), and bound recombinant protein was
eluted from the column using 5 ml of elution buffer (50 mM
sodium phosphate buffer, pH 7, 250 mM imidazole). The
eluted protein was buffer-exchanged by dialysis (with a
3-kDa molecular mass cutoff) into PBS over 24 h at 4 °C,
aliquoted, and stored at 80 °C until needed.
A Bradford assay was carried out to determine protein yield,
and protein purity was visualized by gel electrophoresis on pre-
cast NuPAGE Novex 4–12% BisTris protein gels (Thermo-
Fisher Scientific). For Western blot analysis, proteins were
transferred to a nitrocellulose membrane and blocked with
blocking solution (5% semi-skimmed milk powder in TBST
buffer). Blots were probed with the primary antibody, anti-his-
tidine tag (His6) monoclonal antibody (ThermoFisher Scien-
tific), which had been diluted 1:10,000 in 1% blocking solution.
Blots were thenwashed three timeswithTBST (15min for each
wash) before the secondary antibody, alkaline phosphatase-
conjugated goat anti-mouse IgG (Sigma) diluted 1:15,000 in
TBST buffer, was applied. Antibodies were left to incubate with
the membrane for 1 h before being washed three times with
TBST. Bound antibody was visualized with the substrate
SIGMAFASTTM5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium) (Sigma) and imaged using a G:BOX Chemi
XRQ imager (Syngene).
Inhibition Assays to Determine rFhKT1 and rFhKT1Leu15/
Arg15 Specificity—The inhibitory specificity of rFhKT1 and
rFKT1Leu15/Arg15 was screened using a panel of mammalian
serine and cysteine proteases and F. hepatica cysteine pro-
teases. Enzymes screened for inhibition included the following:
bovine trypsin (Sigma); bovine chymotrypsin (Sigma); human
neutrophil elastase (Elastin Products Co.); bovine thrombin
(Sigma); porcine pancreatic kallikrein (Sigma); human cathep-
sin G (Elastin Products Co.); human cathepsin B (Sigma);
human cathepsin K (Enzo Life Sciences); human cathepsin L
(Sigma); human cathepsin S (Sigma). Purified F. hepatica
cathepsin L1 (FhCL1), F. hepatica cathepsin L2 (FhCL2),
F. hepatica cathepsin B1 (FhCB1), and F. hepatica cathepsin B2
(FhCB2) were expressed as functionally active recombinant
forms in P. pastoris in our laboratory (36).
Reaction conditions and substrates employed for measuring
the activity of each protease are presented in Table 4. rFhKT1
and rFhKT1Leu15/Arg15 (300 nM) were first incubated with
each protease in a 100-l volume reaction buffer for 15 min at
37 °C. Reaction volumes were then brought to 200 l with the
addition of fluorogenic substrate dissolved in reaction buffer,
and the proteolytic activity was measured as RfU in a PolarStar
Omega spectrophotometer (BMGLabTech, UK). Enzyme inhi-
bition studies were performedwith FhCL1 and FhCL2 at differ-
ent pH values ranging from 4.5 to 8.5 using citrate phosphate
buffer. All assays were carried out in triplicate.
To determine inhibition constants, decreasing concentra-
tions (nM) of rFhKT1 and rFhKT1Leu15/Arg15 were exposed to
each protease by serial dilution. Substrate concentrations were
equal to the known Km values of the cysteine proteases. Ki val-
ues were determined using the Morrison equation for tight-
binding inhibition (built into GraphPad Prism 5.0). Briefly, ini-
tial velocities were fitted to Morrison’s equation (Equation 1),
and the resulting apparent Ki (Kiapp) was fitted to Equation 2 to
determine the Ki for FhKT1 and FhKT1Leu15/Arg15 with each
cysteine protease inhibited (59).
 i
o
 1 

E  I  Ki
app 
E I Kiapp2 4EI
2E
(Eq. 1)
TABLE 4
Fluorogenic assay conditions for each protease that inhibition was screened against
Enzyme Assay Buffer Substrate
F. hepatica cathepsin L1 (2.7 nM) 50 mM citrate phosphate buffer, pH 5.5, 2 mM dithiothreitol, 0.01% Brij L23 Z-Leu-Arg-NHMec (20 M)
F. hepatica cathepsin L2 (5 nM) 50 mM citrate phosphate buffer pH 5.5, 2 mM DTT, 0.01% Brij L23 Z-Leu-Arg-NHMec (20 M)
F. hepatica cathepsin B1 (34 nM) 50 mM citrate phosphate buffer pH 5.5, 2 mM DTT, 0.01% Brij L23 Z-Phe-Arg-NHMec (20 M)
F. hepatica cathepsin B2 (180 nM) 50 mM citrate phosphate buffer pH 5.5, 2 mM DTT, 0.01% Brij L23 ZGlyProArgNHMec (20 M)
Human cathepsin L (0.2 nM) 50 mM citrate phosphate buffer pH 5.5, 2 mM DTT, 0.01% Brij L23 Z-Phe-Arg-NHMec (20 M)
Human cathepsin K (2 nM) 50 mM citrate phosphate buffer pH 5.5, 2 mM DTT, 0.01% Brij L23 Z-Phe-Arg-NHMec (20 M)
Human cathepsin S (2 nM) 100 mM sodium acetate buffer, pH 5.6, 1 mM EDTA, 1 mM DTT, 0.01% Brij L23 Z-Val-Val-Arg-NHMec (20 M)
Human cathepsin B (3.6 nM) 50 mM citrate phosphate buffer pH 5.5, 2 mM DTT, 0.01% Brij L23 Z-Phe-Arg-NHMec (20 M)
Trypsin (42 nM) 100 mM Sodium Phosphate Buffer pH 7.6, 1 mM HCl, 20 mM Ca, 0.01% Brij L23 Z-Leu-Arg-NHMec (20 M)
Chymotrypsin (40 nM) 100 mM sodium phosphate buffer, pH 7.6, 1 mM HCl, 20 mM calcium, 0.01% Brij L23 Suc-Ala-Ala-Pro-Phe-NHMec (20 M)
Neutrophil elastase (50 nM) 100 mM Hepes, 500 mM NaCl, pH 7.5, 0.01% Brij L23 MeOSuc-Ala-Ala-Pro-Val-NHMec (20 M)
cathepsin G (100 nM) 100 mM Tris pH 7.5, 0.01% Brij L23 Suc-Ala-Ala-Pro-Pro-NHMec (100 M)
Thrombin (43 pM) 100 mM Tris, 150 mM NaCl, pH 7.4, 0.01% Brij L23 Z-Gly-Pro-Arg-NHMec (2 M)
Kallikrein (150 nM) 20 mM Tris-HCl, pH 7.8, 100 mM NaCl, 0.01% Brij L23 Z-Phe-Arg-NHMec (20 M)
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app Ki1 KmS (Eq. 2)
	i is the initial velocity of a reaction containing the inhibitor,
and 	0 is the initial velocity of a reaction without the inhibitor;
[E] is the concentration of enzyme catalytic sites; [I] is the inhib-
itor concentration; [S] is the substrate concentration, andKm is
the known Michaelis-Menten constant for a given substrate
with a given enzyme. Inhibitor concentrations ranged from 20
to 0.1 nM, providing a range of concentrations above and below
the enzyme concentrations used for the cysteine proteases
inhibited (see Table 1).
To determine the importance of the tertiary structure for the
inhibitory activity of rFhKT1 and rFhKT1Leu15/Arg15, samples
of both inhibitors were reduced and alkylated using tributyl-
phosphine (Sigma) and acrylamide (Sigma), and their inhibi-
tion of FhCL1 and trypsin was measured. Briefly, the inhibitors
were diluted in 40 mM Tris, 5 mM TBP, and 10 mM acrylamide
and incubated for 2 h at room temperature before quenching
the alkylation process by addition of 10 mM DTT (Sigma). For
inhibition assays, untreated and reduced/alkylated rFhKT1 and
rFhKT1Leu15/Arg15 were added to the fluorogenic assays (per-
formed as described above) at a final concentration of 25 nM
(sufficient for 95% protease inhibition by the non-treated
inhibitors). Samples of rFhKT1 and rFhKT1Leu15/Arg15 taken
after quenching of the alkylating reagent samples were kept at
4 °C for 10 days and then assayed for inhibitory activity as
above.
Inhibition of rFhCL1 and rFhCL2 Auto-catalytic Activation
by rFhKT1 and rFhKT1Leu15/Arg15—Unprocessed FhCL1
zymogen (37 kDa, 1.35 M, 1 g) and rFhKT1 or
rFhKT1Leu15/Arg15 (6.5 M, 1 g) were premixed in citrate
phosphate buffer, pH4.5, and incubated at 37 °C for 45min. For
comparison, FhCL1 zymogen was also incubated in citrate
phosphate buffer, pH 4.5, in the presence of 1 g of BPTI. As a
control for auto-catalytic activation of FhCL1, activation was
also carried out in the absence of inhibitor, which has previ-
ously been shown to be successful at pH 4.5 (34). Following
incubation at 37 °C for 45 min, the cysteine protease inhibitor
E-64 (100M)was immediately added to the samples to prevent
any further potential proteolysis by the cysteine protease. A
sample of the FhCL1 zymogen was also used for comparison,
whereby E-64 was immediately added to prevent any auto-cat-
alytic activation. Samples were analyzed by LDS-electrophore-
sis using precast NuPAGE Novex 4–12% BisTris protein gels
(ThermoFisher Scientific), stained with Biosafe Coomassie
(Bio-Rad), and imaged using a G:BOX Chemi XRQ imager
(Syngene).
Stability of the rFhKT1-Cysteine Protease Complex—F.
hepatica cathepsin L1 that was fully activated at pH 4.5 for 1 h
(25 kDa, 2M,1g) was incubated in the presence or absence
of rFhKT1 (6.5 M,1 g) in citrate phosphate buffer, pH 5.5,
and incubated at 37 °C. The reaction was monitored for 6 h
using the peptide substrate Z-Phe-Arg-NHMec. Samples of the
reaction were removed at 1, 2, and 6 h and added immediately
to the cysteine protease inhibitor E-64 (100 M) to prevent any
further potential proteolysis by the cysteine protease. These
samples were then analyzed by LDS-electrophoresis and by
Western blot analysis with rabbit anti-rFhKT1 polyclonal anti-
bodies (prepared by Eurogentec, Lie`ge, Belgium) and anti-His
tag monoclonal antibodies (Sigma). To determine the long
term stability of FhCL1 inhibition by rFhKT1, theseweremixed
as described above, and enzyme activity in samples with and
without inhibitor was monitored over the course of 7 days.
Pulldown of Cysteine Protease from Adult F. hepatica Excre-
tory-Secretory Products—Adult F. hepatica parasites (flukes)
were obtained from lamb livers sourced from an abattoir in
Northern Ireland, United Kingdom. Upon collection, adult
F. hepatica were washed with PBS (containing 0.1% glucose)
and maintained in RPMI 1640 culture medium (ThermoFisher
Scientific) containing 2 mM L-glutamine (ThermoFisher Scien-
tific), 30 mM Hepes (ThermoFisher Scientific), and 0.1% glu-
cose at two flukes/ml. Ten g of rFhKT1 was added to one
culture of media, although, as a control, no inhibitor was added
to a similar parasite culture. After 5 h of incubation at 37 °C, the
parasite culture media were collected and centrifuged at 300	
g for 10 min and then at 700 	 g for 30 min (both at 4 °C) to
remove large debris (e.g. parasite eggs). Then, a 500-l bed vol-
ume of pre-washed Ni-NTA beads was added to each media
and mixed by rotating for 1 h at 4 °C. The Ni-NTA beads were
then centrifuged in a bench topmicrocentrifuge at 100	 g, and
the supernatantwas decanted and stored. The pelletedNi-NTA
beads were washed twice with wash buffer before elution with
100 l of elution buffer (see above). Column flow-through and
eluted samples were analyzed on precast NuPAGE Novex
4–12% BisTris protein gels (ThermoFisher Scientific), stained
with Biosafe Coomassie, and imaged using a G:BOX Chemi
XRQ imager (Syngene).
The cysteine protease activity of the media before and after
the pulldown with Ni-NTA beads was determined by fluoro-
genic assays using the cathepsin L substrate Z-Phe-Arg-
NHMec. An26-kDa protein band that had been pulled down
from the medium to which rFhKT1 was added was character-
ized by LC-MS/MS analysis at the Fingerprints Proteomics
Facility, University of Dundee, Scotland, United Kingdom.
MolecularModeling of rFhKT1 and rFhKT1Leu15/Arg15 Pro-
tease Inhibition—The crystal structure of BPTI with the PDB
code of 3OTJ (60) was used to build the homology model of
FhKT1 using Prime 4.0 (61, 62) with the energy-based setting.
The obtained homology model was first docked to the crystal
structure of FhCL1 previously reported by us (PDB code 2O6X)
(36) using the HEX 6.1 protein-protein docking program (63)
and subjected to molecular dynamics simulations using Mac-
roModel 10.8. In docking, the shape-based and electrostatic-
based assessment of binding was conducted with over 100 gen-
erated and analyzed docking solutions. The docking solution in
which the P1 Leu15 of FhKT1 is pointed to the active site of
FhCL1 was selected for molecular dynamics simulations. 10 ns
of molecular dynamics simulations and 5000 steps of followed
minimization were conducted in implicit solvent at a tempera-
ture of 300K to obtain the final complex.OPLS_2005 force field
was used in MacroModel calculations. A similar docking and
simulation procedure was used to study FhKT1 binding with
human cathepsins K, L, S, and B (PDB codes 1YK7, 4AXM,
3N3G, and 3K9M, respectively). The image with the molecular
models was prepared with Maestro 10.2.
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